A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects

Summary

This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics. In the single ascending dose (SAD) part, healthy adult subjects will receive one dose of TQA3038 or placebo, administered subcutaneously (SC).

Timeline

Start

2023-11-30

Primary completion

2024-12

Completion

2025-12

Drugs

Indications